Tuberculosis is caused by Mycobacterium tuberculosis, and the problem of its drug resistance has become increasingly prominent in recent years, attracting widespread attention globally. Currently, the situation of drug-resistant tuberculosis is grim, and effective strategies are urgently needed to deal with it. Understanding the drug resistance mechanism and treatment status of drug-resistant tuberculosis can provide an important basis for clinical prevention and treatment of drug-resistant tuberculosis. This paper reviews the progress of drug resistance mechanism and treatment of drug-resistant tuberculosis, in order to provide a reference for clinical intervention.

1.卢春容, 谭卫国, 陆普选, 等. 2023年WHO全球结核病报告: 全球与中国关键数据分析[J]. 新发传染病电子杂志, 2023, 8(6): 73-78. [Lu CR, Tan WG, Lu PX, et al. WHO global tuberculosis report 2023: analysis of global and Chinese key data[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(6): 73-78.] DOI: 10.19871/j.cnki.xfcrbzz.2023.06.014.

2.任坦坦, 邓国防, 付亮, 等. 2020 WHO全球结核报告:全球与中国关键数据分析[J].新发传染病电子杂志, 2020, 5(4): 280-284. [Ren TT, Deng GF, Fu L, et al. 2020 WHO global tuberculosis report:analysis of global and Chinese key data[J]. Electronic Journal of Emerging Infectious Diseases, 2020, 5(4): 280-284.] DOI: 10.19871/j.cnki.xfcrbzz.2020.04.015.

3.刘方珉, 吴春峰, 吴国柱, 等. 上海市耐多药结核病患者经济负担研究[J]. 中国卫生资源, 2023, 26(1): 42-49. [Liu FM, Wu CF, Wu GZ, et al. Study on the economic burden of multidrug-resistant tuberculosis patients in Shanghai[J]. China Health Resources, 2023, 26(1): 42-49.] DOI: 10.3969/j.issn.1007-953X.2023.01.008.

4.World Health Organization. Global tuberculosis report 2022[S]. 2022.

5.舒薇, 刘宇红. 世界卫生组织《2023年全球结核病报告》解读[J]. 结核与肺部疾病杂志, 2024, 5(1): 15-19. [Shu W, Liu YH. Interpretation of the World Health Organisation's Global Tuberculosis Report 2023[J]. Journal of Tuberculosis and Lung Disease, 2024, 5(1): 15-19.] DOI: 10.19983/j.issn.2069-8493.2024006.

6.Gygli SM, Borrell S, Trauner A, et al. Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives[J]. FEMS Microbiol Rev, 2017, 41(3): 354-373. DOI: 10.1093/femsre/fux011.

7.陈连勇, 茹浩浩, 杨星, 等. 云南省异烟肼耐药结核分枝杆菌katG和inhA基因突变特征[J]. 昆明医科大学学报, 2022, 43(8): 28-33. [Chen LY, Ru HH, Yang X, et al. Characteristics of isoniazid-resistant Mycobacterium tuberculosis katG and inhA gene mutations in Yunnan Province[J]. Journal of Kunming Medical University, 2022, 43(8): 28-33.] DOI: 10.12259/j.issn.2095-610X.S20220803.

8.徐峰, 饶跃峰, 张幸国, 等. 宁波地区结核分枝杆菌基因突变位点确证及与异烟肼、利福平耐药关系研究 [J]. 中国现代应用药学, 2020, 37(20): 2511-2515. [Xu F, Rao YF, Zhang XG, et al. Confirmation of Mycobacterium tuberculosis gene mutation loci and its relationship with isoniazid and rifampicin resistance in Ningbo[J]. China Modern Applied Pharmacy, 2020, 37(20): 2511-2515.] DOI: 10.13748/j.cnki.issn1007-7693.2020.20.014.

9.Narmandakh E, Tumenbayar O, Borolzoi T, et a1. Genetic mutations associated with isoniazid resistance in mycobacterium tuberculosis in Mongolia[J]. Antimicmb Agents Chemother, 2020, 64(7): e00537-20. DOI: 10.1128/AAC.00537-20.

10.Sharma P, Singh R. GeneXpert MTB/RIF based detection of rifampicin resistance and common mutations in rpoB gene of mycobacterium tuberculosis in tribal population of District Anuppur, Madhya Pradesh, India[J]. J Clin Diagn Res, 2020, 14(9): LM01-LM03. DOI: 10.7860/JCDR/2020/45362.14035.

11.Solo ES, Nakajima C, Kaile T, et al. Mutations in rpoB and katG genes and the inhA operon in multidrug-resistant Mycobacterium tuberculosis isolates from Zambia[J]. J Glob Antimicrob Resist, 2020, 22: 302-307. DOI: 10.1016/j-jgar.2020.02.026.

12.Li MC, Lu J, Lu Y, et a1. rpoB mutations and effects on rifampin resistance in mvcobacterium tuberculosis[J]. Infect Drug Resist, 2021, 14: 4119-4128. DOI: 10.2147/1DR.S333433．

13.王婷, 焦伟伟, 申阿东. 结核分枝杆菌乙胺丁醇耐药机制的研究进展[J]. 遗传, 2016, 38(10):  910-917. [Wang T, Jiao WW, Shin AD. Progress in the study of ethambutol resistance mechanism of Mycobacterium tuberculosis[J]. Genetics, 2016, 38(10): 910-917.] DOI: 10.16288/j.yczz.16-111.

14.许河南, 杨红慧, 赖聪娟, 等. 浙江省丽水市结核分枝杆菌临床分离株耐药性及基因突变情况[J]. 疾病监测, 2023, 38(1): 51-56. [Xu HN,Yang HH, Lai CJ, et al. Drug resistance and gene mutation of clinical isolates of Mycobacterium tuberculosis in Lishui City, Zhejiang Province[J]. Disease Surveillance, 2023, 38(1): 51-56.] DOI: 10.3784/jbjc.202205260243.

15.于圣铭, 夏良华, 詹佳欢, 等. 江西省耐多药结核分枝杆菌链霉素基因突变特征[J]. 实用医学杂志, 2024, 40(1): 91-96. [Yu SM, Xia LH, Zhan JH, et al. Characteristics of streptomycin gene mutations in multidrug-resistant Mycobacterium tuberculosis in Jiangxi Province[J]. Journal of Practical Medicine, 2024, 40(1): 91-96.] DOI: 10.3969/j.issn.1006-5725.2024.01.016.

16.Che Y. Bo D, Lin X. et al. Phenotypic and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates in Ningbo, China[J]. BMC Infect Dis, 2021, 21(1): 605. DOI: 10.1186/s12879-021-06306-1.

17.Li K, Yang Z, Gu J, et al. Characterization of pncA mutations and prediction of PZA resistance in mycobacterium tuberculosis c1inical isolates from Chongqing, China[J]. Front Microbiol, 2020, 11: 594171. DOI: 10.3389/fmicb.2020.594171．

18.夏强, 刘海灿, 赵秀芹, 等. 耐多药结核分枝杆菌对氨基糖苷类及多肽类药物交叉耐药相关基因突变特征分析[J]. 温州医科大学学报, 2022, 52(10): 823-828. [Xia Q, Liu HC, Zhao XQ, et al. Characterisation of gene mutations associated with cross-resistance to aminoglycosides and peptides in multidrug-resistant Mycobacterium tuberculosis[J]. Journal of Wenzhou Medical University, 2022, 52(10): 823-828.] DOI: 10.3969/j.issn.2095-9400.2022.10.008.

19.秦娅莉, 陈静, 李军, 等. 肺结核患者氟喹诺酮类耐药影响因素预测模型的构建与验证:基于LASSO-Logistic回归模型[J]. 中国全科医学, 2024, 27(30): 3776-3783. [Qin YL, Chen J, Li J, et al. Construction and validation of a predictive model of factors influencing fluoroquinolone resistance in patients with pulmonary tuberculosis: based on LASSO-Logistic regression model[J]. Chinese Family Medicine, 2024, 27(30): 3776-3783.] DOI: 10.12114/j.issn.1007-9572.2023.0909.

20.Devasia R, Blackman A, Eden S, et al. High proportion of fluoroquin-olone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility[J]. J Clin Microbiol, 2012, 50(4): 1390-1396. DOI: 10.1128/JCM.05286-11.

21.Zhang Z, Lu J, Wang Y, et al. Prevalence and molecular characterization of fluoroquinolone - resistant Mycobacterium tuberculosis isolates in China[J]. Antimicrob Agents Chemother, 2014, 58(1): 364-369. DOI: 10.1128/AAC.01228-13.

22.Zhang ZD, Zhao YL, Li ZH, et al. Mutations in the thymidylate synthase gene is a major mechanism in the para-aminosalicylic acid resistance of M. tuberculosis[J]. Chin J Tub Res Dis, 2007, 30(9): 683-685. https://pubmed.ncbi.nlm.nih.gov/18070553/.

23.Wei W, Yan H, Zhao J, et al. Multi-omics compari sons of p-aminosalicylic acid (PAS) resistance in folC mutated and un- mutated Mycobacterium tuberculosis strains[J]. Emerg Microbes Infect, 2019, 8(1): 248-261. DOI: 10.1080/22221751.2019.1568179.

24.Gao M, Gao J, Xie L, et a1．Early outcome and safety of bedaquiline-containing regimens for treatment of MDR-and XDR-TB in China: amuhicentre study[J]. Clin Microbiol Infect, 2021, 27: 597-602. DOI: 10.1016/j.cmi.2020.06.004.

25.Stephanie F, Saragih M, Tambunan USF. Recent progress and challenges for drug-resistant tuberculosis treatment[J]. Pharmaceutics, 2021, 13(5): 592. DOI: 10.3390/pharmaceutics13050592.

26.程志忠. 耐多药肺结核患者相关因素分析[J]. 中国健康教育, 2007, 23(4): 308-309. [Cheng ZZ. Analysis of factors associated with multidrug-resistant tuberculosis patients[J]. China Health Education, 2007, 23(4): 308-309.] DOI: 10.3969/j.issn.1002-9982.2007.04.024.

27.首都医科大学附属北京胸科医院／北京市结核病胸部肿瘤研究所,中国防痨协会《中国防痨杂志》编辑委员会. 耐药肺结核全口服化学治疗方案中国专家共识(2021年版)[J]. 中国防痨杂志, 2021, 43(9): 859-866. DOI: 10.3969/j.issn.1000-6621.2021.09.002.

28.World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment: online annexes[S]. 2020.

29.World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment[EB/OL]. (2019-03-20)[2024-05-31]. https://www.who.int/publications/i/item/9789241550529.

30.中华医学会结核病学分会. 抗结核新药贝达喹啉临床应用专家共识(2020年更新版)[J]. 中华结核和呼吸杂志, 2021, 44(2): 81-87. DOI: 10.3760/cma.j.cn112147-20200714-00805.

31.Mi J, Liang Y, Liang J, et al. The research progress in immunotherapy of tuberculosis[J]. Frontiers in Cellular and Infection Microbiology, 2021: 1138. DOI: 10.3389/fcimb.2021.763591.

32.文雨, 杨帆, 汤杰, 等. 分枝杆菌膜蛋白3 (MmpL3)抑制剂在抗结核领域的研究进展[J].中国药物化学杂志, 2023, 33(8): 618-629, 633. [Wen Y, Yang F, Tang J, et al. Research progress of Mycobacterium avium subspecies membrane protein 3 (MmpL3) inhibitors in the field of anti-tuberculosis[J]. Chinese Journal of Medicinal Chemistry, 2023, 33(8): 618-629, 633.] DOI: 10.14142/j.cnki.cn21-1313/r.2023.08.006.

33.Rao M, Ligeiro D, Maeurer M. Precision medicine in the clinical management of respiratory tract infections including multidrug-resistant tuberculosis: learning from innovations in immuno-oncology[J]. Curr Opin Pulm Med, 2019, 25(3): 233-241. DOI: 10.1097/MCP.0000000000000575.

34.王宇. 耐多药肺结核防治管理工作方案[M]. 北京: 军事医学科学出版社, 2012: 16-33.

35.宋凌云, 张忆琳, 孙峰, 等. 持续提高耐药结核病治疗安全性的挑战与对策[J]. 中华传染病杂志, 2023, 41(12): 797-801. [Song LY, Zhang YL, Sun F, et al. Challenges and countermeasures to continuously improve the safety of drug-resistant tuberculosis treatment[J]. Chinese Journal of Infectious Diseases, 2023, 41(12): 797-801.] DOI: 10.3760/cma.j.cn311365-20230729-00020.

36.《中国防痨杂志》编委会, 中国医疗保健国际交流促进会结核病防治分会全国耐药结核病协作组. 耐药结核病化疗过程中药品不良反应处理的专家共识 [J]. 中国防痨杂志, 2019, 41(6): 591-603. DOI: 10.3969/j.issn.1000-6621.2019.06.003.